RSS

Sanofi

Global biopharmaceutical company, Sanofi, has reached a civil settlement with the US Securities and Exchange Commission (SEC), leading to a full resolution of the commission’s investigation into the company more

News

Sanofi Genzyme — specialty care global business unit of French pharma company Sanofi — has launched its multiple sclerosis (MS) drug in India, however, according to GlobalData, it should be cautious of fierce generic competition… more

News

Cablivi (caplacizumab) has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the treatment of a rare blood-clotting disorder, acquired thrombotic thrombocytopenic purpura (aTTP) more

News

Sanofi and Advent International have finalised negotiations for the acquisition of Zentiva — Sanofi’s European generics business — with both companies signing a Share Purchase Agreement worth €1.9 billion. more

News

Sanofi has acquired all outstanding shares, warrants and convertible bonds of Ablynx, following the expiration of the squeeze-out procedure. more

News

A brief round-up of some of the developments in the industry including a step in the right direction for oral insulin and an overview of Alantra Pharma’s Fast 50 index… more

Opinion

CDMO, Recipharm, has acquired Sanofi’s manufacturing centre and business located in Holmes Chapel, which will provide the company with a platform to take advantage of the growing respiratory drug market. more

News

Biopharmaceutical companies, Sanofi and Ablynx, have announced the successful results of the initial tender offer period for Sanofi to acquire outstanding shares of Ablynx. more

News

The US Food and Drug Administration (FDA) has accepted priority review of the biologics licence application (BLA) for cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC)... more

News

The marketing authorisation application (MAA) for cemiplimab as a potential treatment for advanced cutaneous squamous cell carcinoma (CSCC) has been accepted for review by the European Medicines Agency (EMA). more

News

The European Medicines Agency (EMA) has accepted for review an application for an add-on maintenance treatment in certain adults and adolescents (12 years and older) with inadequately controlled moderate-to-severe asthma, Dupixent (dupilumab). more

News

The European Medicines Agency (EMA) has accepted Sanofi’s regulatory submission for sotagliflozin, a potential treatment for type 1 diabetes, for review. more

News

Plans have been announced by Sanofi and Regeneron to make Praluent (alirocumab) more accessible and affordable for those patients with the greatest health risk and unmet need. more

News

Sanofi has completed its acquisition of Bioverativ for $105 per share in cash. As a result, Bioverativ is now a fully owned subsidiary of Sanofi. more

News

The US Food and Drug Administration (FDA) has accepted the supplemental biologics licence application (sBLA) of Dupixent (dupilumab) for review, revealed joint developers of the drug, Regeneron and Sanofi. more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

Sanofi has requested a review by the European Medicines Agency (EMA) of its treatment for sleeping sickness, fexinidazole, which it is developing in collaboration with the Drugs for Neglected Disease initiative (DNDi). more

News

Sanofi is to acquire all outstanding ordinary shares of a biopharmaceutical company that is currently focused on the discovery and development of Nanobodies, Ablynx. more

News

A definitive acquisition agreement has been formed between Sanofi and biopharmaceutical company, Bioverativ, which will see Sanofi acquire all the outstanding shares of Bioverativ for an equity value of approximately $11.6 billion. more

News

Sanofi and Regeneron have revealed that they will accelerate and expand investment for the clinical development programmes of cemiplimab in oncology and dupilumab in type 2 allergic diseases. more

News